Roles of the Tumor Suppressor p53 and the Cyclin-dependent Kinase Inhibitor p21WAF1/CIP1 in Receptor-mediated Apoptosis of WEHI 231 B Lymphoma Cells

By Min Wu,* Robert E. Bellas,* Jian Shen,‡ and Gail E. Sonenshein*

From the *Department of Biochemistry and the ‡Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts 02118

Summary

Treatment of WEHI 231 immature B lymphoma cells with an antibody against their surface immunoglobulin M (anti-IgM) induces apoptosis and has been studied extensively as a model of self-induced B cell tolerance. Since the tumor suppressor protein p53 has been implicated in apoptosis in a large number of cell types and has been found to be mutated in a variety of B cell tumors, here we sought to determine whether p53 and the p53 target gene cyclin-dependent kinase inhibitor p21WAF1/CIP1 were involved in anti-IgM-induced cell death. Anti-IgM treatment of WEHI 231 cells increased expression of p53 and p21 protein levels. Ectopic expression of wild-type p53 in WEHI 231 cells induced both p21 expression and apoptosis. Ectopic expression of p21 similarly induced apoptosis. Rescue of WEHI 231 cells from apoptosis by co-stimulation with CD40 ligand ablated the increase in p21 expression. Lastly, a significant decrease in anti-IgM-mediated apoptosis was seen upon downregulation of endogenous p53 activity by expression of a dominant-negative p53 protein or upon microinjection of an antisense p21 expression vector or antibody. Taken together, the above data demonstrate important roles for p53 and p21 proteins in receptor-mediated apoptosis of WEHI 231 B cells.

Key words: p53 tumor suppressor • p21WAF1/CIP1 • apoptosis • WEHI 231 B-lymphocytes • CD40 ligand

The WEHI 231 lymphoma has been used as a model of self-induced B cell tolerance (1). These cells express surface IgM (1–3), and cross-linking of these surface immunoglobulin receptors with an anti-IgM antibody inhibits DNA synthesis (1, 4). Anti-IgM treatment is followed by cell cycle arrest in the late G1 phase followed by apoptosis (5–8). Because of these features, WEHI 231 cells have been used extensively as a model of clonal deletion of B cells, facilitating dissection of molecular pathways leading to cell death. For example, we recently demonstrated that anti-IgM treatment of these cells causes a drop in activity of the nuclear factor (NF)-κB/Rel transcription factor family, resulting in decreased c-myc expression and induction of cell death (9–12).

A growing number of gene products have been revealed as components of the machinery leading to cell death. Among these, p53 is of particular interest. The p53 protein, originally identified as a cellular nuclear phosphoprotein bound to the large transforming antigen of the SV40 DNA virus (13, 14), has been shown to play important roles in control of progression through G1 into S phase, DNA repair, differentiation, tumor formation, and apoptosis (15–17). Induction of p53 is often associated with activation of cell death, and ectopic expression of p53 can induce apoptosis (18). Thymocytes and hematopoietic cells from mice lacking a p53 gene show resistance to radiation and drug-induced apoptosis (19, 20), and fibroblasts from these mice show resistance to apoptosis (21). Interestingly, anti-IgM–induced cell death of immature B cells from mice null for the p53 gene was significantly reduced (22). The mechanism by which p53 exerts these effects is not clear, but seems to depend on the ability of p53 protein to act as a transcription factor.

One of the important p53 transcriptional target genes is the cyclin-dependent kinase (CDK) inhibitor p21WAF1/CIP1 (23–26). The p21 protein can convert active CDK to inactive species, controlling and coordinating cell cycle pro-
gression (27). The increase in p21 levels elicited by p53 protein upon cellular damage caused by irradiation or other toxic agents leads to CDK inhibition and cell cycle arrest (28, 29). Moreover, p21 activity has been implicated in apoptosis. Ectopic p21 expression induces cell death in MCF-7 breast carcinoma cells, and p21 levels increase during apoptosis of the R T4 human bladder tumor cell line (30–32). These findings suggest that at least some of the ability of p53 to promote apoptosis is mediated through its effects on p21 expression. Here we have investigated the involvement of p53 and its putative target gene p21 in apoptosis of WEHI 231 cells induced by anti-IgM treatment. Our results indicate p53 and p21 play important roles as intermediates in receptor-mediated apoptosis of these immature B lymphoma cells.

Materials and Methods

Cell Culture and Treatment Conditions. WEHI 231 cells were maintained at 37°C in DMEM supplemented with 10% fetal bovine serum (FBS), 0.35% glucose, 4 mM glutamine, nonessential amino acids, 100 U/ml penicillin, 100 µg/ml streptomycin, and 50 µM 2-ME as previously described (9). Before treatment, cells were diluted to a density of 4 × 10⁵ cells/ml with fresh warm media and allowed to incubate for a minimum of 4–5 h. Cells were treated with 1:1,000 dilution anti-IgM, WEHI 231 cells were incubated with CD40L fusion protein (1:10), consisting of the extracellular domains of CD40L and CD8α, and anti-CD8 (1:100) plus anti-IgM, as previously described (33). Stable temperature-sensitive p53-transfected WEHI 231 cells, prepared as described below, were cultured at 38.5°C. Where indicated, untreated cultures were shifted to 32.5°C to induce wild-type p53 activity.

Cell Death Assays. For analysis of DNA laddering, ∼10⁶ cells were used per sample according to the procedure of Smith et al. (34) as we have previously described (10, 11). For trypan blue analysis, cells were incubated with 0.2% trypan blue for 10–20 min and the percentage of cells excluding dye (viable cells) determined by examination under phase-contrast microscopy at ×100.

Construcion of Transfected Cell Lines. Electroporation of WEHI 231 cells was performed essentially as described (9, 10). WEHI 231 cells in exponential growth were washed once with medium and resuspended at a concentration of 2 × 10⁶ cells/ml in DMEM supplemented with 20% FBS. Cells (250 µl) were preincubated on ice for 10 min with DNA (20–40 µg). Cells were transfected by electroporation at 240 V and 960 µl. The cell suspension was mixed with 1.75 ml of complete medium, and incubated for 10 min at room temperature. Cells were then treated with 1:1,000 dilution anti-IgM, WEHI 231 cells were incubated with CD40L fusion protein (1:10), consisting of the extracellular domains of CD40L and CD8α, and anti-CD8 (1:100) plus anti-IgM, as previously described (33). Stable temperature-sensitive p53-transfected WEHI 231 cells, prepared as described below, were cultured at 38.5°C. Where indicated, untreated cultures were shifted to 32.5°C to induce wild-type p53 activity.

Mice and Animals. N. othen Biotas analysis. Cytoplasmic R N A was isolated from 2 × 10⁶ cells per sample. Cells were washed twice in ice cold PBS, resuspended in 400 µl of cold TKM, and swelled on ice for 10 min. After lysis upon addition of 20 µl 10% N P-40, the nuclei were removed by centrifugation. The resulting cytoplasmic supernatant was extracted with phenol/chloroform/isomyl alcohol (10:10:1). R N A was precipitated from the aqueous supernatant with 0.1 vol of 3 M N aC (pH 5.2) and 2.5 vol of absolute ethanol, and dissolved in diethyl pyrocarbonate-treated water. The p53 probe pLTR p53GVal135 (35) was labeled by the random primer method of Feinberg and Vogelstein (39). Hybridization was performed as previously described (40). M irroinjection Analysis. For microinjection analysis, a pO-PR SVI-p21 construct with reverse orientation of the p21 C D N A insert was prepared. This vector expresses a noncoding p21 transcript (antisense) and was termed pO PR SVI-anti-p21. Similarly, a human p27 C D N A insert was cut from vector pGLu-p27H (p provided by Dr. Y. Xiong) with HindIII and BamHI, and used to replace the CAT gene of pO PR SVI CAT in an orientation yielding expression of antisense p27 R N A. This expression vector was termed pO PR SVI-anti-p27. Alternatively, affinity-purified anti-
to immunoblotting with a mouse monoclonal antibody. Detection was achieved using a horseradish peroxidase-conjugated secondary antibody and chemiluminescence as previously described (10). (b) p21 analysis. Total cellular proteins were prepared from WEHI 231 cells treated with anti-IgM for 0, 2, 4, 6, 8, 10, or 12 h, and samples (20 mg) were subjected to immunoblotting for expression of the CDK inhibitor p21 using an affinity-purified rabbit antibody (sc-397, Santa Cruz Biotechnology).

Results

Figure 1. Anti-IgM treatment induces p53 and p21 proteins. (a) p53 analysis. Nuclear proteins were isolated from exponentially growing WEHI 231 cells treated with anti-IgM for 0, 2, 4, 6, 8, 10, or 12 h, and samples (20 mg) were subjected to immunoblotting for p53 expression with a mouse monoclonal antibody. Detection was achieved using a horseradish peroxidase-conjugated secondary antibody and chemiluminescence as previously described (10). (b) p21 analysis. Total cellular proteins were prepared from WEHI 231 cells treated with anti-IgM for 0, 2, 4, 6, 8, 10, or 12 h, and samples (50 mg) were subjected to immunoblotting for expression of the CDK inhibitor p21 using an affinity-purified rabbit antibody (sc-397, Santa Cruz Biotechnology).

Body preparations against p21 or p27 (sc-397 and sc-528, respectively; Santa Cruz Biotechnology) were used. WEHI 231 cells were allowed to attach to tissue culture plastic in the presence of culture medium containing 0.4% FBS, and were supplemented with 20 mM Hepes, pH 7.3. After 30 min of incubation at 37°C, duplicate areas (containing ~200–300 cells/sample) were encircled. For microinjection of expression plasmids, DNA samples were adjusted to 1 mg/ml in 130 mM KCl, and 10 mM sodium phosphate buffer, pH 7.3. Microinjections were performed using a Narishige micromanipulator (Narishige Co., Ltd., Tokyo, Japan) and borosilicate glass capillaries (tip diameter: 0.2 mm) under conditions of constant nitrogen flow at 0.4 pounds per square inch. After microinjection, cloning rings were placed over the microinjected areas and the medium was replaced with 10% FBS/DMEM. After 30 min of incubation at 37°C, cells were removed by gentle trituration, transferred to multiwell plates, and incubated at 37°C in the presence of anti-IgM. After 45 h, 0.1 vol trypan blue solution (0.04% final) was added to the wells and the wells were incubated for another 15 min, then the percentage of trypan blue positive was determined by phase-contrast microscopy. Alternatively, cells were microinjected with 4 mg of affinity-purified antibody in the absence or presence of cognate peptide. After microinjection, cells were treated with anti-IgM and processed after 18 h, as above.

Ectopic Expression of p53 Induces Apoptosis of WEHI 231 Cells. To determine whether ectopic expression of p53 protein can induce the death of WEHI 231 cells, stably transfected WEHI 231 cell lines expressing a temperature-sensitive murine p53 protein were prepared by using the expression vector pLTR p53cGVal135 (35). At the nonpermissive temperature of 32.5°C, these transfectants express a p53 that is wild type; at 38.5°C, they express a dominant-negative p53 that abrogates the endogenous p53 function (35–37).

Northern and immunoblot analyses were used to verify the ectopic expression of p53 in the pLTR p53cGVal135 transfected lines maintained at 38.5°C. Cytoplasmic RNA samples (20–30 mg) were subjected to Northern blotting using the murine p53 DNA pLTR p53cGVal135 as probe (35). Bottom panel shows ethidium bromide staining of the 28S and 18S rRNA on the Northern blot, which indicates equal loading and RNA integrity. (b) p53 protein analysis. Total cellular proteins were extracted with RIPA buffer from p53#11, p53#16, and control Neo cells, and samples (20 mg) subjected to immunoblotting using the p53 antibody Pa421. (d) p21 protein analysis. Cultures of p53#11 and p53#16 cell lines were kept at 38.5°C or switched to 32.5°C, and total cellular proteins isolated after 24 h. Samples (50 mg) were analyzed for p21 protein by immunoblotting using an affinity-purified rabbit antibody against p21 protein (sc-397, Santa Cruz Biotechnology).
was isolated from clones p53#11 and p53#16 and pSV2neo cells, and samples subjected to Northern blotting (Fig. 2a). At the nonpermissive temperature, clones p53#11 and p53#16 expressed high levels of p53 mRNA, whereas barely detectable levels of p53 were noted in the pSV2neo clone. Ethidium bromide staining of the 28S and 18S rRNA in the gel indicated equal loading and integrity of the RNA samples. Furthermore, ectopic expression of p53 protein was confirmed using immunoblotting of total protein extracts from the above cell lines (Fig. 2b). Lastly, to verify that these clones expressed functional p53 in a temperature-dependent fashion, the effects of a temperature shift on endogenous p21 expression were monitored (Fig. 2c). 24 h after shifting to the permissive temperature, p21 protein levels were dramatically induced. These results confirm that the transfectants express a functional p53 protein.

Ectopic Expression of p53 Induces Apoptosis of WEHI 231 Cells. To determine whether induction of p53 expression activates apoptosis, DNA fragmentation assays were performed. The p53 clones p53#11, p53#16, and Neo cells were analyzed 24 h after a temperature switch to 32.5°C. Significant DNA laddering was observed after induction of wild-type p53 expression in the p53#11 and p53#16 cell lines (Fig. 3a). As expected, only a low basal level of DNA laddering was detectable in the Neo cells after 24 (Fig. 3a) or 48 (data not shown) h. Thus, ectopic expression of wild-type p53 is sufficient to induce apoptosis of WEHI 231 cells.

To obtain more quantitative assessment of this killing, analysis of cell viability was performed using trypan blue exclusion at various times after temperature shift. The p53#11, p53#16, and control Neo cells were cultured in duplicate at 32.5°C for 0, 24, 48, or 72 h, and trypan blue-positive cells were measured. Fig. 3b shows that both clone p53#11 and p53#16 exhibited a steady increase in cell death during the time course; the percentage of dead cells increased from 7% (in both) on day 0 to 82 and 84% on day 3 in the p53#11 and p53#16 cultures, respectively. In con-

---

**Figure 3.** Induction of apoptosis by ectopic p53 expression. (a) DNA laddering. The p53 expressing clones p53#11, p53#16, and control Neo cells were cultured at 32.5°C for 0 or 24 h, and subjected to DNA ladder assays (34), as a measure of induction of apoptosis. (b) Trypan blue staining. The p53 expressing clones p53#11 (hatched bars), p53#16 (open bars) and control Neo (filled bars) cells were cultured in duplicate at 32.5°C for 0, 24, 48, or 72 h in 96-well dishes, and induction of cell death determined by trypan blue staining. Numbers of cells stained trypan are plotted as a function of time in hours. The statistical significance was obtained using the Student's t test, and the vertical bars represent the standard deviation.

---

**Figure 4.** Downregulation of endogenous p53 activity inhibits anti-IgM-induced apoptosis. (a) The p53 expressing clone p53#11 and Neo control cells were grown at 38.5°C and treated with anti-IgM for 0, 20, or 32 h, and analyzed for apoptosis by DNA ladder assays (left panel). Alternatively, p53#11 and Neo control cells were cultured in duplicate at 38.5°C and treated with anti-IgM for 48 h, and cell death was analyzed by trypan blue staining (right panel). Data are plotted as the mean percentage of cells stained positive for trypan blue. The statistical significance was obtained using the Student's test, and the vertical bars represent the standard deviation. (b) The p53-expressing clone p53#16 and Neo control cells were cultured at 38.5°C and treated with anti-IgM for 48 h, and analyzed as above. Alternatively, p53#16 and Neo control cells were cultured in duplicate at 38.5°C and treated with anti-IgM for 0 or 48 h, and analyzed by trypan blue staining for cell death. Data are plotted as above.
using a modification of the isopropyl-

-taining an inducible p21 expression vector were prepared to produce apoptosis, stable WEHI 231 cells containing an inducible p21 expression vector were prepared using a modification of the isopropyl-β-d-thiogalacto-pyran-

Figure 5. Ectopic expression of p21 induces WEHI 231 cell death. WEHI 231 cells were electroporated with 30 μg pOPR SV1-p21 and 10 μg p3′SS vector encoding the Lac I repressor and a mixed population of p21 transfectants were selected using 350 μg/ml hygromycin B and 1,000 μg/ml G418. Alternatively, WEHI 231 cells electroporated with control p3′SS were selected with hygromycin alone. (a) p21 protein analysis. Total proteins were prepared from p0 PR SV1-p21 and control p3′SS transfectants after treatment with 20 mM IPTG for 24 h, and samples (50 μg) were subjected to immunoblot analyses for expression of p21. (b) DNA ladder assay. Cultures of the control p0 PR SV1-p21 and p3′SS transfectants were treated with 20 mM IPTG for 24 h and analyzed for apoptosis by a DNA ladder assay. (c) Trypan blue staining. Cultures of the p0 PR SV1-p21 and p3′SS transfectants were treated in duplicate with 20 mM IPTG for 24 h, and extent of cell death was assessed by trypan blue staining. Data are plotted as the mean percentage of cells stained positive for trypan blue. The statistical significance was obtained using the Student’s t test, and the vertical bars represent the standard deviation.

diarylindole-1-β-channel opening to activate the receptor (Fig. 4). 1.2% of p53#11 cells stained positive for trypan blue after 18 h compared with 2.0% of cells not microinjected or 6.5% of cells microinjected with the p21 expression vector. 1.2% of p53#11 cells stained positive for trypan blue after 18 h compared with 2.0% of cells not microinjected or 6.5% of cells microinjected with the p21 expression vector. 1.2% of p53#11 cells stained positive for trypan blue after 18 h compared with 2.0% of cells not microinjected or 6.5% of cells microinjected with the p21 expression vector.
cells microinjected with pBluescript vector DNA (data not shown). Taken together, these results demonstrate that ecotropic p21 expression leads to apoptosis of WEHI 231 cells. CD40L rescue of anti-IgM–induced apoptosis is accompanied by decreased expression of p21. CD40L rescue of WEHI 231 cells from anti-IgM–induced apoptosis is accompanied by maintenance of NF-κB/R el and c-myc expression (33), as well as of cellular proliferation (41). To determine whether CD40L affected p21 expression in response to anti-IgM treatment, exponentially growing WEHI 231 cells were treated with anti-IgM in the presence or absence of CD40L for 0, 8, or 12 h. Total cellular proteins were extracted, and samples were subjected to immunoblotting for p21 protein expression (Fig. 6). Treatment with anti-IgM alone led to the expected induction in p21 protein levels. However, induction of p21 was significantly ablated by cotreatment with CD40L plus anti-IgM (Fig. 6). Thus, CD40L–induced rescue of WEHI 231 cells from receptor-mediated apoptosis is accompanied by a block in the induction of the CDK inhibitor p21.

Reduction of CDK Inhibitor Expression Abolishes Anti-IgM–induced Apoptosis. Since induction of p21 was sufficient to induce apoptosis of WEHI 231 cells, and CD40L rescue prevented the normal increase seen upon anti-IgM treatment, we next sought to determine whether the receptor-mediated increase in p21 expression was a necessary part of the signal transduction pathway(s) leading to apoptosis. WEHI 231 cells were microinjected with pOPRSVI-anti-p21, a plasmid yielding inducible expression of p21 transcript in an antisense orientation, and then treated immediately with anti-IgM. After incubation at 37°C for 45 h, cultures were analyzed for cell viability (Fig. 7). Treatment of nonmicroinjected cells with anti-IgM induced death in 60 ± 1.4% of the cells after 45 h, as previously seen (11). In contrast, only 38.7 ± 6.8% of pOPRSVI-anti-p21 microinjected cells were dead (P < 0.05, Student's t-test). Thus, antisense p21 is capable of inducing a significant amount of protection against anti-IgM–induced apoptosis. Recently, anti-IgM treatment has also been shown to induce expression of another CDK inhibitor, p27kip1 (42). Thus, the effects of antisense expression of p27 in combination with antisense p21 on anti-IgM–mediated apoptosis were similarly assessed. The combination of antisense p21 and antisense p27 provided very significant protection, superior to that with the p21 vector alone. Cells microinjected with the combination of vectors exhibited 15.4 ± 1.1% cell death at 45 h after treatment with anti-IgM.

To inhibit p21 activity more directly, cells were also microinjected with affinity purified antibodies to either p21 or p27 protein, and the effects on anti-IgM–mediated killing assessed. After 18 h, in the absence of microinjection, 41.9 ± 0.1% of cells were trypan blue positive, and this value was essentially unaffected by microinjection of BSA. In contrast, microinjection of an antibody against p21 protein significantly reduced the level of cell death (24.4 ± 0.1%), and this was specific as judged by reversal of protection upon incubation with the cognate peptide. Microinjection of the peptide alone did not affect cell viability (data not shown). Again, inhibition of both p21 and p27 protected to even a greater extent (only 13.7 ± 1.5% cell death). The specificity of the effect of the p27 antibody was also confirmed with its cognate peptide (data not shown). Thus, these results indicate that a portion of the signals leading to apoptosis is dependent on p21; many of the remaining signals appear mediated via a p27 pathway.

Discussion

The results presented here indicate that induction of p53 and p21 proteins after anti-IgM treatment is part of a critical pathway in receptor-mediated apoptosis of WEHI 231 B cells. Treatment of WEHI 231 cells with anti-IgM led to early increases in p53 protein expression and subsequently
to increases in p21 protein levels. Ectopic expression of wild-type p53 induced both p21 expression and apoptosis. Consistent with a direct role for induction of p21 in cell death, ectopic expression of p21 alone also induced apoptosis of WEHI 231 cells. Furthermore, downregulation of endogenous p53 activity by expression of a dominant-negative p53 protein or by p21 antibody or antisense expression significantly ablated receptor-mediated apoptosis. Taken together, the above data demonstrate a pivotal involvement of p53 in anti-IgM–induced apoptosis of WEHI 231 B cells, which is probably mediated, at least in part, by the product of its target gene p21.

Mounting evidence, both in vitro and in vivo, supports a role for p53 function in control of B cell fate. Mutations of the p53 gene have been reported in 41% of Burkitt's lymphomas, 60% of B cell chronic lymphocytic leukemia, and 30% of high-grade non-Hodgkin's lymphomas (for reviews see references 43, 44). In addition, a recent report found p53 abnormalities in 75% of B cell prolymphocytic leukemia (45). Analysis of B cell tumors from p53-null mice revealed significantly decreased levels of immunoglobulin deposition when compared with tumors from wild-type mice (22). Furthermore, the p53-null mice contained more immature B cells in the bone marrow compared with wild-type mice. Importantly, these effects appear to relate to loss of normal receptor-mediated killing of these immature B cells (46). Treatment of the immature B cell population from p53-null mice with anti-IgM resulted in hyperproliferation (46) rather than the typical cell death response seen with immature B cells from normal mice (22), suggesting a role of p53 in control of B cell death. Furthermore, wild-type p53 has been implicated as a control protein in the differentiation pathway of B cells. Ectopic expression of wild-type p53 protein promotes differentiation of the Abelson murine leukemia virus-transformed pre-B cell line L12 (47). Differentiation of the pre-B cell line 702/3 in response to lipopolysaccharide is accompanied by increases in p53 expression (48). Lastly, ectopic expression of a dominant-negative p53 mutant is capable of blocking LPS-mediated differentiation (48).

Our work extends the list of genes whose protein products are involved in receptor-induced apoptotic pathways of WEHI 231 cells. Recent work from our lab has implicated the NF-κB/Rel transcription factor family and the c-myc oncogene as important intermediates in the signal transduction pathway leading to apoptosis (10, 11). Ectopic expression of either c-myc or c-rel prevents anti-IgM-mediated apoptosis; direct inhibition of either c-Myc or Rel activity induces death of WEHI 231 cells (10, 11, 49). One potential model for relating the findings of this work to our previous studies is to postulate that c-myc is upstream of p53. Anti-IgM treatment leads to a transient increase by 1 h followed by eventual downmodulation of NF-κB/Rel activity; these modulations precede concomitant changes in transcription of the c-myc gene, which is strongly regulated by NF-κB/Rel in these cells (9). Interestingly the p53 promoter has been found to be activated by c-Myc in fibroblasts (50, 51). Furthermore, p53 has been found to repress c-myc transcription in a human glial cell line (52), and we have observed that induction of wild-type p53, in our temperature-sensitive p53 lines, led to downregulation of c-myc expression (data not shown). Thus, one can propose that the initial increase in c-Myc expression leads to induction of p53, which then participates in promoting the subsequent downregulation of c-myc expression. The potential interrelationships between c-Myc and p53 expression after anti-IgM treatment, which are probably complex, are currently under investigation.

Anti-IgM has been previously shown to induce expression of p27 protein (42), although the mechanism is unknown. The evidence presented here suggests that p21 and p27 cooperate in mediating anti-IgM–induced apoptosis, as judged by the antisense experiments. Thus, these observations implicate p27 in receptor-mediated apoptosis in WEHI 231 cells. The fact that neither antisense reagent alone gives full protection suggests a divergence in pathways leading to apoptosis of these B cells: portions of the apoptotic signals initiated after cross-linking of surface IgM channel through p21 and others through p27. Thus, these findings suggest the existence of parallel signal transduction pathways diverging from the initiating events mediated by receptor-ligand interaction and working together to promote apoptosis.

We thank Drs. Y. Xiong, S. Hann, and T. Rothstein for generously providing cDNA clones, c-Myc antibody, and CD40 ligand, respectively.

This work was supported by National Institutes of Health grant CA-36355.

Address correspondence to Gail E. Sonenshein, Department of Biochemistry, Boston University School of Medicine, 80 East Concord St., Boston, MA 02118. Phone: 617-638-4120; Fax: 617-638-4252; E-mail: gsonensh@acs.bu.edu

Received for publication 17 November 1997 and in revised form 26 February 1998.

1677 Wu et al.
References

1. Boyd, A.W., and J.W. Schrader. 1981. The regulation of growth and differentiation of a murine B-cell lymphoma. II. The inhibition of WEHI 231 by anti-immunoglobulin antibodies. J. Immunol. 126:2466–2469.

2. Monroe, J.G., and V.L. Seyfert. 1988. Studies of surface immunoglobulin-dependent B cell activation. Immunol. Res. 7:136–151.

3. Ralph, P. 1979. Functional subsets of murine and human B lymphocyte cell lines. Immunol. Rev. 48:107–121.

4. Sonenshein, G.E. 1997. Down-modulation of c-Myc expression induces apoptosis of B lymphocyte models of tolerance. J. Immunol. 20:1405–1407.

5. Meikrantz, W., and R. Schlegel. 1995. Apoptosis and cell cycle. J. Cell. Biochem. 58:160–174.

6. Harris, C.C., and M. Hollstein. 1993. Medical progress: clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 329:1318–1327.

7. Clarke, A.R., C.A. Purdie, D.J. Harrison, R.G. Morris, C.C. Bird, M.L. Hooper, and A.H. Wyllie. 1993. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849–852.

8. Sonenshein, G.E. 1996. Inhibition of NF-kappa B by anti-immunoglobulin antibodies induces death by apoptosis in WEHI 231 B lymphoma cells. Eur. J. Immunol. 26:4682–4690.

9. Lee, H., M. Arsura, M. Wu, M. Duyao, A.J. Buckler, and G.E. Sonenshein. 1995. Role of c-Myc-gene transcription in receptor-mediated apoptosis of the murine B cells WEHI 231 line. J. Exp. Med. 181:1169–1177.

10. Wu, M., H. Lee, R.E. Bellas, L.S. Schauer, M. Arsura, D. Katz, M.J. Fitzgerald, T.L. Rothstein, D.H. Sherr, and G.E. Sonenshein. 1996. Inhibition of Nfic-B/Ri el induces apoptosis of murine B cells. EMBO J. 15:4682–4690.

11. Lee, H., M. Arsura, R.E. Bellas, M.J. Fitzgerald, H. Lee, S.L. Schauer, D.H. Sherr, and G.E. Sonenshein. 1996. Inhibition of c-Myc-expression induces apoptosis of WEHI 231 murine B cells. Mol. Cell. Biol. 16:5015–5025.

12. Sonenshein, G.E. 1997. Down-modulation of c-Myc expression induces apoptosis of B lymphocyte models of tolerance via clonal deletion. J. Immunol. 158:1994–1997.

13. Lane, D.P., and L.V. Schlegel. 1995. T antigen is bound to a host protein in SV40 transformed cells. Nature 278:261–263.

14. Linzer, D.P., and A.J. Levine. 1979. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43–52.

15. Vogelstein, B., and K.W. Kinzler. 1992. p53 function and dysfunction. Cell 70:523–526.

16. Harris, C.C., and M. Hollstein. 1993. Medical progress: clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 329:1318–1327.

17. Carson, D.A., and A. Lois. 1995. Cancer progression and p53. Lancet. 346:1009–1011.

18. Meikrantz, W., and R. Schlegel. 1995. Apoptosis and cell cycle. J. Cell. Biochem. 58:160–174.

19. Clarke, A.R., C.A. Purdie, D.J. Harrison, R.G. Morris, C.C. Bird, M.L. Hooper, and A.H. Wyllie. 1993. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849–852.

20. Clarke, A.R., S. Gledhill, M.L. Hooper, C.C. Bird, and A.H. Wyllie. 1994. p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. Nature 369:1767–1773.

21. Harpe, J., and H. Eick. 1994. The inhibition of NF-kappa B by anti-immunoglobulin antibodies induces apoptosis in WEHI 231 murine lymphoma WEHI 231 cells. EMBO (Eur. Mol. Biol. Organ.) J. 13:2787–2792.

22. Shick, L., J.A. Carman, J.K. Choi, K. Somasundaram, M. Burrell, D.E. Hill, Y.X. Zeng, Y. Wang, K.G. Wiman, K. Salhany, et al. 1997. Decreased immunoglobulin deposition in tumor and increased immature B cells in p53-null mice. Cell Growth Differ. 8:121–131.

23. Harper, J.W., G.R. Adami, N. Wei, K. Keyomarsi, and S.J. Elledge. 1993. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinase. Cell 75:805–816.

24. Xiong, Y., H. Zhang, and D. Beach. 1993. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. G. Enzyme Dev. 4:757–758.

25. Zhang, H., Y. Xiong, and D. Beach. 1993. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complex. Mol. Cell. Biol. 4:897–906.

26. Waga, S., G.J. Hannon, D. Beach, and B. Stillman. 1994. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574–578.

27. Sherr, C.J., and J.M. Roberts. 1995. Inhibitors of mammalian G1 cyclin-dependent kinases. G. Enzyme Dev. 9:1149–1163.

28. El-Deiry, W.S., T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825.

29. Dulic, V., W.K. Kaufmann, S.J. Wilson, T.D. Tlsty, E. Lees, J.W. Harper, S.J. Elledge, and S.I. Reed. 1994. p53-dependent inhibition of cyclin-dependent kinase in human fibroblasts during radiation-induced G 2 arrest. Cell 76:1013–1023.

30. Sheik, M.S., H. R ochefort, and M. Garcia. 1995. Evidence for the expression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cells. O. Enzyme Dev. 11:1899–1905.

31. Sheik, M.S., M. Garcia, Q. Zhan, Y. Liu, and A.J. Fornace Jr. 1996. Cell cycle-independent regulation of p21WAF1/CIP1 and retinoblastoma protein during okadaic acid-induced apoptosis is coupled with induction of Bax protein in human breast carcinoma cells. Cell Growth Differ. 7:1599–1607.

32. Chresta, C.M., J.R. Masters, and J.A. Hickman. 1996. Sensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax: Bcl-2 ratio. Cancer Res. 56:1834–1841.

33. Schauer, S.L., Z. Wang, G.E. Sonenshein, and T.L. Rothstein. 1996. Maintenance of NF-kB-Ri el and c-Myc expression during CD4 ligand rescue of WEHI 231 cells from receptor-mediated apoptosis through modulation of IkB proteins. J. Immunol. 157:81–86.

34. Smith, C.A., G.T. Williams, R. Kingston, E.J. Jenkinson, and E. Elledge. 1993. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinase. Cell 75:805–816.

35. Finlay, C.A., P.W. Hind, T.H. Tan, D. Elyahu, M. Oren, and A.J. Levine. 1989. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell. Biol. 8:531–539.
36. Michalovitz, D., O. Halevy, and M. Oren. 1990. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell. 62:671–680.

37. Martinez, J., I. Georgoff, J. Martinez, and A.J. Levine. 1991. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev. 5:151–159.

38. Hann, S.R., M. Dixit, R.C. Sears, and L. Sealy. 1994. The alternatively initiated c-Myc proteins differentially regulate transcription through a non-canonical DNA-binding site. Genes Dev. 8:2441–2452.

39. Han, S.R., M. Dixit, R.C. Sears, and L. Sealy. 1994. The alternatively initiated c-Myc proteins differentially regulate transcription through a non-canonical DNA-binding site. Genes Dev. 8:2441–2452.

40. Arsura, M., M. Wu, and G.E. Sonenshein. 1996. TGF-β1 inhibits NF-κB activation inducing apoptosis of B cells. Immunity. 5:31–40.

41. Tsubata, T., J. Wu, and T. Honjo. 1993. B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40. Nature. 364:645–648.

42. Ezhevsky, S.A., H. Toyoshima, T. Hunter, and D.W. Scott. 1996. Role of cyclin A and p27 in anti-IgM-induced G1 growth arrest of murine B cell lymphomas. Mol. Biol. Cell. 7:553–564.

43. Newcomb, E.W. 1995. p53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Leuk. Lymphoma. 17:211–221.

44. Ichikawa, A., T. Hotta, and H. Saito. 1993. Mutations of the p53 gene in B-cell lymphoma. Leuk. Lymphoma. 11:21–25.

45. Lens, D., P.J. De Schouver, R.A. Hamoudi, M. Abdul-Rauf, N. Farahat, E. Matutes, T. Crook, M.J. Dyer, and D. Catovsky. 1997. p53 abnormalities in B-cell prolymphocytic leukemia. Blood. 89:2015–2023.

46. Norvell, A., L. Mandik, and J.G. Monroe. 1995. Engagement of the antigen receptor on immature murine B lymphocytes results in cell death by apoptosis. J. Immunol. 154:4403–4413.

47. Shaulsky, G., A. Goldfinger, A. Peled, and V. Rotter. 1991. Involvement of wild type p53 in pre-B-cell differentiation in vitro. Proc. Natl. Acad. Sci. USA. 88:8982–8986.

48. Aloni-Grinstein, R., I. Zan-Bar, I. Albuom, N. Goldfinger, and V. Rotter. 1993. Wild-type p53 functions as a control protein in the differentiation pathway of the B cell-lineage. Oncogene. 8:3297–3305.

49. Wu, M., W. Yang, R.E. Bellas, M. Arsura, L.S. Schauer, D. Katz, M.J. FitzGerald, H.Y. Lee, and G.E. Sonenshein. 1997. c-Myc promotes survival of WEHI 231 B lymphoma cells from apoptosis. Curr. Top. Microbiol. Immunol. 224:91–101.

50. Reisman, D., N.B. Elkind, B. Roy, J. Beamon, and V. Rotter. 1993. c-myc transactivates the p53 promoter through a required downstream CACGTG motif. Cell Growth Differ. 4:57–65.

51. Roy, B., J. Beamon, E. Balint, and D. Reisman. 1994. Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol. Cell. Biol. 14:7805–7815.

52. Moberg, K.H., W.A. Tyndall, and D.J. Hall. 1992. Wild-type murine p53 represses transcription from the murine c-myc promoter in a human glial cell line. J. Cell. Biochem. 49:208–215.